GlassScriptPhysician profile
Jaclynn Green
NPI 1518501394
$5,662.77
in general payments reported to CMS, 2019-2025
43 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $804 · 2023: $1,529 · 2024: $1,221 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.04 | 2021-2025 | |
| Livanova USA, INC. | $488.70 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $476.75 | 2023-2025 | Briviact, Fintepla, Zilbrysq |
| Pfizer INC. | $458.80 | 2023-2025 | |
| Neurelis, INC. | $447.48 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $389.91 | 2022-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $344.83 | 2021-2024 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $265.31 | 2022-2025 | Nuplazid, Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $203.21 | 2021-2025 | Hyqvia, Gammagard |
| Axsome Therapeutics, INC. | $179.03 | 2025 | Symbravo |
| Lundbeck LLC | $177.51 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $149.70 | 2021-2025 | Austedo Xr, Austedo Xr |
| Csl Behring | $130.20 | 2021-2025 | Kcentra, Hizentra |
| Jazz Pharmaceuticals INC. | $117.84 | 2022-2023 | |
| Lilly USA, LLC | $112.50 | 2023-2025 | Amyvid, Kisunla |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $105.33 | 2022-2025 | Onpattro |
| Merz Pharmaceuticals, LLC | $94.37 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Argenx US, INC. | $71.23 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $64.94 | 2023 | Inbrija |
| Almatica Pharma LLC | $55.24 | 2021 | |
| Eisai INC. | $49.65 | 2023-2024 | |
| Tanabe Pharma America, INC. | $43.37 | 2023-2024 | |
| Mdd US Operations, LLC | $40.40 | 2023 | Apokyn |
| Biohaven Pharmaceuticals, INC. | $35.86 | 2021 | |
| Biogen, INC. | $35.12 | 2024-2025 | Skyclarys |
| Impel Pharmaceuticals INC. | $34.87 | 2022-2023 | Trudhesa |
| Ani Pharmaceuticals, INC. | $34.37 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $21.07 | 2022 | |
| Genzyme Corporation | $19.60 | 2021 | |
| Aquestive Therapeutics, INC. | $18.81 | 2021 | |
| Corium, LLC | $18.22 | 2023 | Adlarity |
| Nalu Medical, INC. | $17.67 | 2022 | |
| Emd Serono, INC. | $17.21 | 2024 | |
| Tg Therapeutics, INC. | $16.92 | 2025 | |
| Viz.Ai, INC. | $16.82 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $16.69 | 2023 | Fycompa |
| Aprecia Pharmaceuticals, LLC | $16.19 | 2022 | |
| Aucta Pharmaceuticals, INC. | $16.04 | 2025 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $15.76 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $15.39 | 2024 | Xarelto |
| Springworks Therapeutics, INC. | $15.06 | 2025 | |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grifols USA, LLC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclynn Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.